Gonococcal infections, caused by the bacterium Neisseria gonorrhoeae, are sexually transmitted infections (STIs) with significant public health implications. These infections commonly affect the urogenital tract but can also involve other mucosal surfaces, including the rectum, pharynx, and conjunctiva. Gonorrhea often presents with symptoms such as urethritis, dysuria, and genital discharge in men and cervicitis or pelvic inflammatory disease (PID) in women. However, a substantial number of infections can be asymptomatic, leading to challenges in early detection and treatment. The rise of antibiotic resistance in Neisseria gonorrhoeae poses a considerable threat to effective gonococcal infection management. Over the years, the bacterium has developed resistance to various classes of antibiotics, including penicillins, tetracyclines, and fluoroquinolones. Currently, cephalosporins, particularly ceftriaxone, are the mainstay of treatment. However, there are growing concerns about emerging resistance to this last-line therapy. Addressing the challenge of antibiotic resistance in gonococcal infections requires a multifaceted approach, including enhanced surveillance, research on alternative treatment strategies, and the development of a gonorrhea vaccine. Promoting responsible antibiotic use and implementing comprehensive STI prevention measures are also critical components in mitigating the spread of antibiotic-resistant gonorrhea.